Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06075693 · ClinicalTrials.gov registry record
Cerebrospinal Fluid Biomarkers of Myotonic Dystrophy
A clinical trial of Myotonic Dystrophy Type 1, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- 88
- Enrollment target
- 1
- Study location
NCT06075693 is a study of Myotonic Dystrophy Type 1 that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 88 participants, below the 1,056-participant average among 3 other Myotonic Dystrophy Type 1 trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06075693, a study of Myotonic Dystrophy Type 1, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- 88 participants
- Enrollment target
- 1
- Study location
Study Summary
Myotonic dystrophy is associated with central sleep apnea, excessive daytime sleepiness, diminished working memory, impaired visuospatial skills, and deficits in problem-solving skills. Cerebrospinal fluid (CSF) is a clear, colorless fluid that surrounds and protects the brain. Changes in the composition of CSF can serve as early indicators of changes in brain activity and function. The purpose of this research is to learn about myotonic dystrophy by examining cerebrospinal fluid and brain activity in participants. The tests will be low risk and are well tolerated. The information that we gather from this study may help us evaluate, prevent, diagnose, treat, and improve our understanding of myotonic dystrophy. Funding Source- FDA OOPD
Conditions Studied
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2022-08-01 |
| Est. Completion | 2028-08-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06075693
The ClinicalTrials.gov registry entry for NCT06075693 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,056-participant average among 3 other Myotonic Dystrophy Type 1 trials with a reported enrollment target (92% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myotonic Dystrophy Type 1 appearing as the primary indexed condition, and to 0 interventions.
NCT06075693 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06075693 about?
NCT06075693 is a clinical study titled "Cerebrospinal Fluid Biomarkers of Myotonic Dystrophy". Myotonic dystrophy is associated with central sleep apnea, excessive daytime sleepiness, diminished working memory, impaired visuospatial skills, and deficits in problem-solving skills. Cerebrospinal fluid (CSF) is a clear, colorless fluid that surrounds and protects the brain. Changes in the comp...
What is the current status of trial NCT06075693?
This trial is currently recruiting. The enrollment target is 88 participants. The study started on 2022-08-01. Estimated completion is 2028-08-01.
What conditions does trial NCT06075693 study?
This clinical trial studies the following conditions: Myotonic Dystrophy Type 1.
Who is sponsoring clinical trial NCT06075693?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06075693 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myotonic Dystrophy Type 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Brain Structure and Clinical Endpoints in Myotonic Dystrophy Type 2
RECRUITING
-
Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
RECRUITING
-
Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.